On January 15, 2020 Contextual Genomics, a leading cancer genomics company, and Eastern Ontario Regional Laboratory Association (EORLA), a nonprofit organization offering high quality, patient focused, hospital-based lab services in Eastern Ontario, reported that they have partnered to bring Contextual Genomics’ ctDNA cancer genomic testing to EORLA’s Champlain Local Health Integration Network (CLHIN) of Eastern Ontario, Canada (Press release, Contextual Genomics, JAN 15, 2020, View Source [SID1234553235]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Contextual Genomics has developed the FOLLOW IT cancer panel, a multiplex, next-generation sequencing genomic assay evaluating the mutation status of tumour DNA in plasma, identifying the somatic mutations that have the greatest potential to impact treatment decisions. EORLA will offer FOLLOW IT to its network as a part of Contextual Genomics’ FOLLOW IT Canadian Early Access Program (CEAP). Indicated patients are expected to benefit from this new option by providing a less invasive alternative to tissue biopsy and by the addition of more convenient localized blood draw collection sites.
Contextual Genomics’ Canadian Early Access Program for FOLLOW IT plasma-based genomic cancer testing is underway in British Columbia and Ontario, offering a patient-pay test for individuals with metastatic lung, breast and colorectal cancer. The FOLLOW IT panel tests for actionable mutations, potentially leading to changes in disease management. All CEAP testing is performed in the Contextual Genomics’ clinically accredited laboratory in Vancouver and results are available in 5-10 business days.
"We are excited to be providing access to FOLLOW IT testing through the Contextual Genomics’ Canadian Early Access Program," said Greg Dorion, Vice President, Operations of EORLA. "This offering is in line with EORLA’s purpose – to deliver patient-focused, consistent, high-quality and cost-effective hospital-based laboratory services to meet the needs of Eastern Ontarians."
"The partnership with EORLA, in support of our FOLLOW IT Canadian Early Access Program, is important to Canadians in this region, allowing them better access to important health care. We look forward to working with EORLA to ensure that all cancer patients in their region that would benefit from FOLLOW IT testing will have access through their hospital Network," Michael Ball, Contextual Genomics’ Chief Executive Officer, commented in a statement.